36. Molecular and clinical epidemiology of carbapenem-resistant Enterobacter aerogenes strains isolated from a tertiary hospital in China
Session: Posters in the Park: Posters in the Park
Wednesday, October 3, 2018: 5:30 PM
Room: N Hall D Opening Reception and Posters in the Park Area
Posters
  • idweek poster-v1.pdf (393.4 kB)
  • Background: The more and more frequently reported carbapenem-resistant Enterobacteriaceas called for alarm worldwide. In this study, the resistance mechanism and epidemiology of carbapenem-resistant Enterobacter aerogenes (CREA) which isolated in a Chinese tertiary hospital were investigated.

    Methods: Antimicrobial susceptibility testing of 17 antibiotics were performed. b-lactamase genes were detected. Efflux pump phenotype test and outer membrane porin SDS-PAGE were performed. Clonal relationship was investigated by PFGE (pulsed field gel electrophoresis). S1 nuclease-PFGE, Restriction Fragment Length Polymorphism(RFLP) analysis and plasmid incompatibility groups analysis were performed to analyze blaKPC-2 carrying plasmids. Epidemiological data were collected via history review.

    Results: Only tigecycline and colistin maintained high level susceptibility to 14 CREA isolates. Five distinct groups (PFGE types A–E) were observed. All 14 isolates carried the blaKPC-2. Only one isolates lost Omp36 porin. Efflux pump had no contribution to these 14 isolates. S1 nuclease-PFGE indicated that the size of blaKPC-2 carrying plasmids were among 20kb to 200kb. RFLP analysis divided blaKPC-2 carrying plasmids into 7 groups. Plasmids can be divided into 5 incompatibility groups. Epidemiological and molecular investigations showed that PFGE type A group, including 11 KPC-2-producing clinical isolates, was primarily responsible for the dissemination.

    Conclusion: Our findings suggest further studies should focus on judicious use of available antibiotics and strict implementation of infection-control measures to avoid the rapid spread or clonal dissemination caused by CREA in healthcare facilities

    Min Hao, MD and Xiaohua Qin, MD, Huashan Hospital, Shanghai, China

    Disclosures:

    M. Hao, None

    X. Qin, None

    See more of: Posters in the Park
    See more of: Posters in the Park

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.